| Not Yet Recruiting | Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG T NCT06972615 | BLATAM | Phase 2 |
| Recruiting | Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy NCT07144319 | Photocure | — |
| Not Yet Recruiting | Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients NCT07231809 | AC.TA. S.r.l. | N/A |
| Recruiting | Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladd NCT05962541 | University of Roma La Sapienza | Phase 4 |
| Recruiting | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Ca NCT07283835 | Lepu Biopharma Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, S NCT06990061 | European Organisation for Research and Treatment of Cancer - EORTC | N/A |
| Recruiting | A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer NCT07206225 | Pfizer | Phase 1 |
| Not Yet Recruiting | T-Control® Safety for Cytostatics Management NCT06678633 | Rethink Medical SL | N/A |
| Not Yet Recruiting | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC NCT07189793 | First Affiliated Hospital of Wenzhou Medical University | Phase 2 |
| Not Yet Recruiting | Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Musc NCT07198451 | Shanghai University of Traditional Chinese Medicine | Phase 2 / Phase 3 |
| Withdrawn | A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BC NCT06816017 | Hoffmann-La Roche | Phase 1 |
| Recruiting | Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer NCT06781879 | Jakob Kristian Jakobsen | Phase 4 |
| Recruiting | A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) NCT06929286 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Recruiting | A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer NCT06503614 | John Sfakianos | Phase 2 |
| Recruiting | A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder C NCT07036731 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Recruiting | Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer NCT06972771 | Yunnan Cancer Hospital | — |
| Recruiting | A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With In NCT06245603 | Istituto Oncologico Veneto IRCCS | N/A |
| Recruiting | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) NCT06637423 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | Precise Neoadjuvant Chemoresection of Low Grade NMIBC NCT06227065 | University of Bern | Phase 2 |
| Recruiting | A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive NCT06632964 | The Affiliated Hospital of Xuzhou Medical University | Phase 1 |
| Completed | Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resectio NCT07347132 | Lahore General Hospital | N/A |
| Recruiting | Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC NCT06663137 | Relmada Therapeutics, Inc. | Phase 2 |
| Not Yet Recruiting | HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer NCT06327932 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 3 |
| Active Not Recruiting | Study of CG0070 After Transurethral Resection in Patients With IR NMIBC NCT06253845 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) NCT05825950 | University of Texas Southwestern Medical Center | — |
| Active Not Recruiting | A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer NCT06181266 | Prokarium Ltd | Phase 1 |
| Active Not Recruiting | The Role of Universal Cancer Only Marker SIX6 in Diagnosing Non-Muscle Invasive Bladder Cancer NCT07252297 | Xijing Hospital | N/A |
| Recruiting | Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoper NCT06241755 | Chengdu CoenBiotech Co., Ltd | Phase 3 |
| Recruiting | Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer NCT06187506 | Fudan University | Phase 2 |
| Active Not Recruiting | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT NCT06111235 | CG Oncology, Inc. | Phase 3 |
| Recruiting | Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance NCT05796375 | White River Junction Veterans Affairs Medical Center | Phase 2 |
| Completed | Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC) NCT06126796 | Mayo Clinic | — |
| Recruiting | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasi NCT05951179 | Protara Therapeutics | Phase 2 |
| Unknown | The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients NCT06245759 | Huazhong University of Science and Technology | — |
| Active Not Recruiting | Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) NCT05981131 | ImmunityBio, Inc. | — |
| Active Not Recruiting | BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants NCT05943106 | AstraZeneca | Phase 3 |
| Recruiting | RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Exp NCT05957757 | RenJi Hospital | Phase 2 |
| Not Yet Recruiting | RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer NCT05996952 | West China Hospital | Phase 2 |
| Recruiting | A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer NCT05710848 | SURGE Therapeutics | Phase 1 / Phase 2 |
| Completed | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER NCT05945108 | AstraZeneca | — |
| Recruiting | The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients Wit NCT06287541 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Active Not Recruiting | External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group NCT05864599 | Pharmalink | — |
| Recruiting | Effects of Microbiological and Immunological Factors on the Lower Urinary Tract NCT07494864 | University of Zurich | — |
| Completed | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasi NCT05085990 | Protara Therapeutics | Phase 1 |
| Recruiting | Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) NCT05790850 | University of Virginia | N/A |
| Recruiting | Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG NCT05672615 | Johns Hopkins University | — |
| Recruiting | AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer NCT05002556 | Association Francaise d'Urologie | — |
| Active Not Recruiting | Intravesical BCG vs GEMDOCE in NMIBC NCT05538663 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Unknown | The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Blad NCT05704231 | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | N/A |
| Active Not Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors NCT05544552 | Tyra Biosciences, Inc | Phase 1 / Phase 2 |
| Recruiting | A Phase I Intravesical PPM Therapy for NMIBC NCT05519241 | VA Office of Research and Development | Phase 1 |
| Unknown | Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Inv NCT05580354 | Ruijin Hospital | Phase 4 |
| Recruiting | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer NCT05483868 | Aura Biosciences | Phase 1 |
| Unknown | Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients NCT05547516 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Recruiting | OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer NCT05232136 | Binhui Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer NCT05327647 | CHU de Quebec-Universite Laval | Phase 2 |
| Completed | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIB NCT05375903 | UroGen Pharma Ltd. | Phase 1 |
| Recruiting | Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer NCT05337397 | Jørgen Bjerggaard Jensen | — |
| Unknown | Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients NCT05332353 | Mansoura University | — |
| Completed | En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer NCT05223491 | Jørgen Bjerggaard Jensen | N/A |
| Completed | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasi NCT05085977 | Protara Therapeutics | Phase 1 |
| Completed | Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer NCT06205277 | University of Trieste | — |
| Terminated | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer ( NCT05014139 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Recruiting | Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment NCT05126472 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intrav NCT04736394 | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Phase 3 |
| Terminated | LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors NCT04690699 | Istari Oncology, Inc. | Phase 1 / Phase 2 |
| Unknown | Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer NCT04859751 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention NCT04375813 | Robert Svatek | Phase 2 |
| Unknown | Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Ri NCT05626101 | Al-Azhar University | N/A |
| Completed | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive t NCT04387461 | CG Oncology, Inc. | Phase 2 |
| Unknown | Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer NCT04664816 | Mansoura University | N/A |
| Unknown | Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer NCT04644835 | Mansoura University | N/A |
| Active Not Recruiting | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Ca NCT04452591 | CG Oncology, Inc. | Phase 3 |
| Completed | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk NCT03914794 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Unknown | Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer NCT03950362 | Institut Paoli-Calmettes | Phase 2 |
| Completed | Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Gueri NCT05675176 | National and Kapodistrian University of Athens | — |
| Unknown | Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer NCT05671900 | Clinical Hospital Centre Zagreb | N/A |
| Completed | Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer NCT06235853 | Wroclaw Medical University | — |
| Active Not Recruiting | A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer NCT04165317 | Pfizer | Phase 3 |
| Active Not Recruiting | Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor NCT04100733 | Jørgen Bjerggaard Jensen | N/A |
| Completed | Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior Histo NCT06020807 | Nucleix Ltd. | — |
| Unknown | Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy NCT04943094 | Aarhus University Hospital | — |
| Active Not Recruiting | CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer NCT03933826 | University of Washington | — |
| Completed | Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC) NCT06767982 | Ankara University | Phase 4 |
| Completed | A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection o NCT03664258 | Cepheid | — |
| Unknown | A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer NCT03560479 | Hamlet Pharma AB | Phase 1 / Phase 2 |
| Completed | Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer NCT03081858 | Lipac Oncology LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-musc NCT03528694 | AstraZeneca | Phase 3 |
| Unknown | Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) NCT03421236 | Patrice Jichlinski | Phase 1 |
| Unknown | "En Bloc" Resection of NMIBC: a Prospective， Single Centre，Randomized Study NCT03221062 | Tongji Hospital | Phase 4 |
| Unknown | Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride A NCT04490993 | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Phase 3 |
| Terminated | Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC NCT02982395 | Samyang Biopharmaceuticals Corporation | Phase 3 |
| Unknown | Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC NCT02895620 | Institut Claudius Regaud | N/A |
| Completed | Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladd NCT02969109 | Genomic Health®, Inc. | — |
| Completed | CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) NCT02316171 | Viralytics | Phase 1 |
| Active Not Recruiting | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer NCT02138734 | ImmunityBio, Inc. | Phase 1 / Phase 2 |
| Completed | Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) R NCT04498702 | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Phase 2 |
| Unknown | Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instil NCT02075060 | Poitiers University Hospital | Phase 2 |
| Recruiting | Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. NCT06167356 | IRCCS San Raffaele | — |
| Withdrawn | A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instil NCT01799499 | UroGen Pharma Ltd. | N/A |
| Completed | Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer NCT01731652 | Telormedix SA | Phase 2 |
| Terminated | A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer NCT01625260 | Altor BioScience | Phase 1 / Phase 2 |
| Terminated | Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Mainte NCT01310803 | Endo Pharmaceuticals | Phase 3 |
| Completed | Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer NCT01458847 | BioCis Pharma Ltd | Phase 1 |
| Completed | Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging NCT01004211 | Paolo Puppo | N/A |
| Completed | Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer NCT02343614 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | Phase 2 |
| Available | An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive NCT06443944 | CG Oncology, Inc. | — |